<DOC>
	<DOCNO>NCT02405377</DOCNO>
	<brief_summary>Patients moderate high risk contrast induce nephropathy ( CIN ) receive sufficient hydration application contrast prevent CIN , hydration could obviously increase preload congestive heart failure ( CHF ) patient . It important make individual hydration protocol patient dysfunction heart renal reduce incidence rate CIN . This prospective , randomize , double-blind , comparative clinical trial randomly select 264 patient estimate glomerular filtration rate , ( eGFR ) &lt; 60 ml/min per 1.73 m2 CHF undergo coronary angiography receive either convention hydration ( n=132 ) central venous pressure ( CVP ) guide hydration ( n=132 ) .</brief_summary>
	<brief_title>Central Venous Pressure Guided Hydration Prevention Contrast-Induced Nephropathy</brief_title>
	<detailed_description>Investigators enrol 264 patient February 2014 February 2015 , principal inclusion criterion include CHF : leave ventricular eject fraction ( LVEF ) &lt; = 50 % ; moderate severe CKD diagnose eGFR 15 59 mL/min per 1.73 m2 , calculate via abbreviate Modification Diet Renal Disease ( MDRD ) study equation SCr obtain within 72 hour enrollment , patient schedule undergo diagnostic cardiac angiography percutaneous coronary intervention . We randomly assign eligible patient 1:1 ratio either CVP guide therapy standard hydration administration protocol . Investigators use fluid type commercially available 0.9 % sodium chloride patient . Investigators monitor CVP place 5-French catheter jugular vein . Investigators record CVP commercially available haemodynamic monitoring software . In CVP guide group fluid rate adjust accord CVP follow : 3 mL/kg/h CVP low 6 mmHg , 1.5 mL/kg/h pressure 6-12 mmHg , 1mL/kg/h pressure high 12 mmHg . The control group hydrate 1 mL/kg per h. The fluid rate set start procedure ( contrast exposure ) . Thus , study group receive intravenous fluid duration different rate . All study participant receive intra-arterial Visipaque ( 320 mg I/ml ; GE Healthcare ) iso-osmolar contrast medium . Primary end point study incidence CIN : The median peak increase serum creatinine concentration day 0 ( contrast administer ) day 7 . Definition CIN absolute increase serum creatinine ( SCr ) &gt; 0.5 mg/dl relative increase &gt; 25 % compare baseline SCr . Definition non-Q-wave myocardial infarction creatine kinase-myocardial band enzyme elevation 3 time upper normal value without new Q wave electrocardiogram . Definition Q-wave myocardial infarction presence new pathologic Q wave electrocardiogram conjunction elevation creatine kinase great 3 time normal value . All adverse clinical event well study end point monitor adjudicated independent event committee . Each patient contact every week administration contrast , investigated dialysis main cardiovascular event ( myocardial infarction , acute heart failure death ) , record adverse event .</detailed_description>
	<mesh_term>Cardio-Renal Syndrome</mesh_term>
	<criteria>1. congestive heart failure : objective evidence decrease leave ventricular eject fraction ( LVEF ) &lt; = 50 % ; 2. moderate severe chronic kidney disease define eGFR 15 59 mL/min per 1.73 m2 , calculate via abbreviate Modification Diet Renal Disease ( MDRD ) study equation SCr obtain within 72 hour enrollment ; 3. patient schedule undergo diagnostic cardiac angiography percutaneous coronary intervention . 1. hemodialysisdependent patient ; 2. complicate severe shortterm progressive disease ; 3 . Patients &lt; 18 year ; 4. pregnancy ; 5. emergency cardiac catheterisation ( eg , primary percutaneous coronary intervention STsegment elevation myocardial infarction ) ; 6. exposure radiographic contrast medium within previous 7 day ; 7. acute decompensated heart failure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>contrast-induced nephropathy</keyword>
	<keyword>hydration</keyword>
	<keyword>Percutaneous coronary intervention</keyword>
</DOC>